Cross-market cost-effectiveness analysis of erlotinib as first-line maintenance treatment for patients with stable non-small cell lung cancer | Zendy

A. Vergnenègre | Zendy; Ray | Zendy; C. Chouaïd | Zendy; Enzo Grossi | Zendy; Bischoff | Zendy; Heigener | Zendy; Stefan Walzer | Zendy

Open Access

Cross-market cost-effectiveness analysis of erlotinib as first-line maintenance treatment for patients with stable non-small cell lung cancer

Author(s) -

A. Vergnenègre,

Ray,

C. Chouaïd,

Enzo Grossi,

Bischoff,

Heigener,

Stefan Walzer

Publication year - 2012

Publication title -

clinicoeconomics and outcomes research

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.591

H-Index - 27

ISSN - 1178-6981

DOI - 10.2147/ceor.s25923

Subject(s) - erlotinib , medicine , oncology , lung cancer , life expectancy , population , incremental cost effectiveness ratio , erlotinib hydrochloride , randomized controlled trial , cost effectiveness , intensive care medicine , cost effectiveness analysis , cancer , epidermal growth factor receptor , risk analysis (engineering) , environmental health

Platinum-doublet, first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) is limited to 4-6 cycles. An alternative strategy used to prolong the duration of first-line treatment and extend survival in metastatic NSCLC is first-line maintenance therapy. Erlotinib was approved for first-line maintenance in a stable disease population following results from a randomized, controlled Phase III trial comparing erlotinib with best supportive care. We aimed to estimate the incremental cost-effectiveness of erlotinib 150 mg/day versus best supportive care when used as first-line maintenance therapy for patients with locally advanced or metastatic NSCLC and stable disease.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research